• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Landec Corporation Announces Sale of Curation Foods' Fresh Packaged Salads and Vegetables Business for $73.5 Million in Cash

    12/13/21 6:03:02 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LNDC alert in real time by email

    Strategic sale results in a CDMO-focused company aligned with attractive growth categories and end markets

    Net proceeds from the sale will be allocated towards debt pay down, resulting in significant deleveraging

    Announces fiscal second quarter earnings call on January 5, 2022

    SANTA MARIA, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company focused on its growing Lifecore Biomedical ("Lifecore") business – a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today announced that it has completed the sale of its Curation Food's fresh packaged salads and vegetables business for $73.5 million in cash to Taylor Farms Retail, Inc. ("Taylor Farms"). Net proceeds from the transaction will be used to repay borrowings under the Company's credit facility, which the Company believes will drive significant deleveraging and strengthen the Company's financial position, allowing management to devote even greater resources and investment to Lifecore.

    Dr. Albert Bolles, Chief Executive Officer of Landec Corporation, said, "Closing on this transaction today marks an important milestone in Project SWIFT – the Company's framework for enhancing the value and performance of the Curation Foods business – and demonstrates ongoing efforts to extract value from our non-core assets and re-orient the Company around our rapidly growing Lifecore Biomedical business. We will be deploying the net proceeds from the sale directly toward debt paydown, which will reduce our balance sheet leverage and allow us to channel our resources to more fully support the growth and expansion of the Lifecore Biomedical business. While there's more work to do, the Company is laser-focused on the business and assets that are growing at a greater rate, produce more attractive margins, and have value that is presently underappreciated. Going forward, we will maintain our continued commitment to maximize the value of our Lifecore and remaining Curation Foods businesses. We are excited about the path ahead."

    Transaction Highlights

    The transaction included the sale of all of the assets exclusively associated with Curation Foods' core fresh vegetable bag, tray, and salad businesses, including its flagship brand Eat Smart®, representing revenue of approximately $366 million in the trailing twelve month period ended August 29, 2021. The transaction does not include the Company's avocado products or technology businesses (Yucatan Foods, O Olive Oil & Vinegar®, and patented BreatheWay® packaging technology), which the Company has retained. The Company also has agreed to provide certain customary transition services to Taylor Farms related to the Business for up to six months, in exchange for a monthly fee.

    John D. Morberg, Chief Financial Officer of Landec Corporation, stated, "We are pleased to complete this sale and simultaneously pay down debt by $67.9 million, net, after deducting for total transaction related costs and debt prepayment fees. This is a major step in simplifying the business and has an immediate effect of reducing our leverage ratio, which we believe will provide Landec with greater financial flexibility to achieve our long-term growth and value objectives at Lifecore."

    Curation Foods' results of operations related to the assets sold will be reported as discontinued operations beginning in the fiscal third quarter of 2022.

    William Blair & Company, L.L.C. served as financial advisor and Latham & Watkins LLP served as legal advisor to Landec.

    Fiscal Second Quarter Conference Call

    Landec Corporation will host a conference call to discuss fiscal 2022 second quarter financial results and implications of the transaction on January 5, 2022, including updated guidance for the go-forward business. The live webcast can be accessed via Landec's website on the Investor Events & Presentations page. The webcast will be available for 30 days.

    Date: Wednesday, January 5, 2022

    Time: 2:00 p.m. Pacific time (5:00 p.m. Eastern time)

    Direct Webcast link: http://ir.Landec.com/events.cfm

    To participate in the conference call via telephone, dial toll-free: 1-877-407-3982 (U.S.) or 1-201-493-6780 (International). Please call the conference telephone number 5-10 minutes prior to the start time so the operator can register your name and organization. If you have any difficulty with the webcast or connecting to the call, please contact ICR at (646) 277-1263.

    A replay of the call will be available through Wednesday, January 12, by calling toll-free: 1-844-512-2921 (U.S.)or 1-412-317-6671 (International), and entering code13725662.

    About Landec Corporation

    Landec Corporation (NASDAQ:LNDC) is a leading innovator of diversified health and wellness solutions with two operating businesses: Lifecore Biomedical, Inc. and Curation Foods, Inc. Landec designs, develops, manufactures and sells products for the biopharmaceutical and food industries. Lifecore Biomedical is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. As a leading manufacturer of premium, injectable grade Hyaluronic Acid, Lifecore brings 35 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. Curation Foods is focused on innovating and distributing plant-based foods with 100% clean ingredients to retail, club and foodservice channels throughout North America. Curation Foods brands include Yucatan® and Cabo Fresh® avocado products and O Olive Oil & Vinegar® premium artisan products. For more information about the Company, visit Landec's website at www.landec.com.

    Important Cautions Regarding Forward-Looking Statements

    This press release contains forward-looking statements regarding future events and our future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange Act of 1934. Words such as "anticipate", "estimate", "expect", "project", "plan", "intend", "believe", "may", "might", "will", "should", "can have", "likely" and similar expressions are used to identify forward-looking statements. All forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially, including such factors among others, as the timing and expenses associated with operations, the ability of the Company to recognize the anticipated benefits of the transaction with Taylor Farms, future liabilities that may arise from the transaction with Taylor Farms, including from indemnification or retained assets, the ability of the Company to perform any remaining obligations pursuant to the transaction with Taylor Farms, the ability to successfully operate the remaining Curation Foods businesses, litigation that may arise from the transaction with Taylor Farms, the ability to achieve acceptance of the Company's new products in the market place, weather conditions that can affect the supply and price of produce, government regulations affecting our business, the timing of regulatory approvals, uncertainties related to COVID-19 and the impact of our responses to it, the ability to successfully integrate Yucatan Foods into the Curation Foods business, and the mix between domestic and international sales. For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to our filings with the Securities and Exchange Commission, including the risk factors contained in our most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K. Forward-looking statements represent management's current expectations and are inherently uncertain. Except as required by law, we do not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.

    Landec Corp. Contact Information:

    Investor Relations

    Jeff Sonnek

    (646) 277-1263

    [email protected] 



    Primary Logo

    Get the next $LNDC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LNDC

    DatePrice TargetRatingAnalyst
    8/11/2022$14.00Mkt Perform → Outperform
    Barrington Research
    7/20/2022$13.00Overweight
    Stephens
    4/6/2022Outperform → Mkt Perform
    Barrington Research
    10/4/2021$15.00 → $14.00Buy
    Roth Capital
    7/30/2021$12.00 → $15.00Buy
    Roth Capital
    More analyst ratings

    $LNDC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lifecore Biomedical Announces Completion of Corporate Name Change

    Common stock expected to begin trading tomorrow under new Nasdaq ticker symbol "LFCR" Lifecore global headquarters relocated to Chaska, MN Launches new investor relations website: ir.lifecore.com CHASKA, Minn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has completed its transition to Lifecore Biomedical, including the change of its name from Landec Corporation to Lifecore Biomedical, Inc. In connection with this change, the Company's common stock is also expected to commence trading under its new Nasdaq ticker symbol "LFCR" tomorrow, N

    11/14/22 9:01:56 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifecore Biomedical to Participate in the Stephens Annual Investment Conference on Thursday, November 17, 2022

    CHASKA, Minn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Lifecore" or the "Company"), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. ("Lifecore") and Curation Foods, Inc. ("Curation Foods"), – today announced that Jim Hall, CEO of Landec Corporation & President of Lifecore, and John Morberg, CFO will be hosting a fireside chat at the Stephens Annual Investment Conference in Nashville, TN. The Company will participate in a fireside chat on Thursday, November 17th at 8:00 AM CT. The live audio webcast will be available to all interested parties through a live audio webcast accessible on the Company's investor rel

    11/10/22 8:00:00 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Landec Expects to Change Corporate Name to Lifecore Biomedical and Ticker Symbol to "LFCR" on November 14

    CHASKA, Minn., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Lifecore" or the "Company") today announced that it expects to effect its previously announced corporate name change to Lifecore Biomedical, Inc. and to cause its common stock to begin trading on Nasdaq under the ticker symbol "LFCR" prior to market open on November 14, 2022. This new ticker symbol will replace the Company's current ticker symbol "LNDC," which has been used since its initial public offering in 1996. The new corporate name and ticker symbol align with the Company's ongoing strategic transformation toward its high-growth, high-value CDMO business that is focused on the development, fill and f

    11/1/22 8:00:00 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LNDC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Schechter Joshua converted options into 9,554 shares, increasing direct ownership by 20% to 57,667 units (SEC Form 4)

    4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

    2/2/24 7:02:00 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Calloway Nathaniel converted options into 3,981 shares, increasing direct ownership by 17% to 28,069 units (SEC Form 4)

    4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

    2/2/24 6:41:59 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Obus Nelson converted options into 9,554 shares, increasing direct ownership by 12% to 88,687 units (SEC Form 4)

    4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

    2/2/24 6:40:32 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LNDC
    SEC Filings

    View All

    Landec Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

    2/16/24 4:12:45 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Landec Corporation

    SCHEDULE 13G - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)

    2/14/24 3:39:52 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Landec Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

    1/12/24 4:51:33 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LNDC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Landec upgraded by Barrington Research with a new price target

    Barrington Research upgraded Landec from Mkt Perform to Outperform and set a new price target of $14.00

    8/11/22 9:23:39 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stephens initiated coverage on Landec with a new price target

    Stephens initiated coverage of Landec with a rating of Overweight and set a new price target of $13.00

    7/20/22 7:31:01 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Landec downgraded by Barrington Research

    Barrington Research downgraded Landec from Outperform to Mkt Perform

    4/6/22 9:22:55 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LNDC
    Leadership Updates

    Live Leadership Updates

    View All

    Custom Made Meals Appoints Molly Montgomery as Chief Executive Officer

    Custom Made Meals (CMM), a leading national provider of fresh, ready-to-cook (RTC) entrees, appetizers, and sides for the meat and deli departments of retail grocery and club stores, announced today that it has appointed Molly Montgomery as CEO, effective today. Ms. Montgomery has served on the CMM Board of Directors since it was acquired by Stellex Capital Management LLC (Stellex) in May of 2021 and will continue to serve on the board in her new role. Stellex is a middle-market private investment firm with strong experience in the food industry. Ms. Montgomery succeeds Dale Easdon, who has led the Company as CEO for the past three years and has worked closely with management to ensure a sm

    5/17/22 8:30:00 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LNDC
    Financials

    Live finance-specific insights

    View All

    Landec Corporation Reports First Quarter Fiscal Year 2023 Results

    Lifecore segment revenues increased 8.0% to $23.7 million in fiscal 2023 first quarter versus the prior year periodLifecore segment EBITDA increased 8.1% to $2.5 million in fiscal 2023 first quarter versus the prior year periodReiterates fiscal 2023 full year guidance for LifecoreCorporate rebranding to Lifecore Biomedical continues to progress SANTA MARIA, Calif. and MINNEAPOLIS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. ("Lifecore") and Curation Foods, Inc. ("Curation Foods"), reported results for the fiscal 2023 first

    10/6/22 7:15:00 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Landec Corporation Revises First Quarter 2023 Earnings Conference Call for October 6, 2022 at 8:00 a.m. ET

    SANTA MARIA, Calif. and MINNEAPOLIS, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company focused on its growing Lifecore Biomedical ("Lifecore") business – a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today announced a change to its previously announced fiscal 2023 first quarter earnings conference call date in recognition of Yom Kippur. The Company will now report financial results before the market opens on T

    9/28/22 4:05:00 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Landec Corporation Sets First Quarter 2023 Earnings Conference Call for October 5, 2022 at 2:00 p.m. PT

    SANTA MARIA, Calif. and MINNEAPOLIS, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company focused on its growing Lifecore Biomedical ("Lifecore") business – a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today announced that it will host a conference call to discuss fiscal 2023 first quarter financial results. The live webcast can be accessed via Landec's website on the Investor Events & Presentations page. The web

    9/21/22 8:00:00 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LNDC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Landec Corporation (Amendment)

    SC 13G/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)

    2/9/24 9:59:14 AM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Landec Corporation (Amendment)

    SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)

    1/4/24 4:00:21 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Landec Corporation (Amendment)

    SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)

    8/15/23 5:07:46 PM ET
    $LNDC
    Biotechnology: Pharmaceutical Preparations
    Health Care